TRAX
First Tracks Biotherapeutics, Inc. NMS
Healthcare
·Biotechnology
·United States
$18.87
Mkt Cap $655.0M
52w Low $14.79
34.0% of range
52w High $26.80
50d MA $22.09
200d MA $22.09
P/E (TTM)
—
Forward P/E
-5.65x
EPS (TTM)
—
Forward EPS
$-3.34
Price/Book
—
Book Value
—
Revenue TTM
—
Gross Margin
0.0%
Oper. Margin
0.0%
Net Margin
0.0%
ROE
—
ROA
—
Debt/Equity
—
Current Ratio
—
Div Yield
—
Div Rate
—
Payout Ratio
—
Beta
—
Shares Out
$34.0M
Float
—
Short Ratio
—
Short % Float
—
Inst. Held
—
Insider Held
—
Avg Volume
154,741
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Ret 1d | Alpha 1m |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | JP Morgan | Initiates | Overweight | $31 | — | — |
| Apr 22, 2026 | Barclays | Initiates | Overweight | $40 | — | — |
| Apr 21, 2026 | UBS | Initiates | Buy | $45 | — | — |
About
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorp…
Data updated apr 22, 2026 6:02pm
· Source: Yahoo Finance